{"entity":{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","aka":[],"tldr":"A phase 1/2 trial of Oregovomab, Bevacizumab, Paclitaxel / nab-paclitaxel in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.","summary":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer is a phase 1/2 interventional study registered as NCT04938583 by CanariaBio Inc., with 54 participants planned, started 2021-03-17 and due to reach its primary completion in 2025-10-30. Interventions recorded: Oregovomab, Bevacizumab, Paclitaxel, Carboplatin. Conditions listed: Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04938583","url":"https://clinicaltrials.gov/study/NCT04938583"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-sensitive-ovarian-cancer"],"sections":[],"technologies":["antiangiogenic","cytotoxic-chemotherapy","monoclonal-antibody","platinum"],"targets":[],"drugs":["oregovomab","bevacizumab","paclitaxel","carboplatin"],"companies":["canariabio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04938583","phase":"1/2","setting":"Phase 1b/2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Bevacizumab, Paclitaxel Carboplatin as a Combinatorial Strategy in Subjects With BRCA-wild Type Platinum Sensitive Recurrent Ovarian Cancer","sponsor":"CanariaBio Inc.","participation":[{"nct":"NCT04938583","source":"https://clinicaltrials.gov/study/NCT04938583","fetchedAt":"2026-10-07T16:53:30.712Z","studySha256":"46424af632e85704256e18c9d1d6325419fac4df7f3a4a442510fee371284538","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-04-06","leadSponsor":"CanariaBio Inc.","collaboratorCount":1,"minimumAge":"19 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":54,"enrolmentType":"ESTIMATED","siteCount":6,"recruitingSiteCount":0,"countries":["South Korea"]}],"started":"2021-03-17","startedType":"actual","enrolled":54,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04938583/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"canariabio","kind":"company","name":"CanariaBio","route":"/companies/canariabio/"}]}}